The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database.
Clinical Trials have emerged as the main force in driving the development of medicine. However, little is known about the current status of clinical trials regarding nasopharyngeal carcinoma (NPC). This study aimed at providing a comprehensive landscape of NPC-related trials on the basis of Clinical...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5931495?pdf=render |
| _version_ | 1818908251911094272 |
|---|---|
| author | Hao Peng Lei Chen Yu-Pei Chen Wen-Fei Li Ling-Long Tang Ai-Hua Lin Ying Sun Jun Ma |
| author_facet | Hao Peng Lei Chen Yu-Pei Chen Wen-Fei Li Ling-Long Tang Ai-Hua Lin Ying Sun Jun Ma |
| author_sort | Hao Peng |
| collection | DOAJ |
| description | Clinical Trials have emerged as the main force in driving the development of medicine. However, little is known about the current status of clinical trials regarding nasopharyngeal carcinoma (NPC). This study aimed at providing a comprehensive landscape of NPC-related trials on the basis of ClinicalTrials.gov database.We used the keyword "nasopharyngeal carcinoma" to search the ClinicalTrials.gov database and assessed the characteristics of these trials.Up to December 30, 2016, 462 eligible trials in total were identified, of which 222 (48.0%) recruited only NPC (NPC trials) and the other 240 (52.0%) recruited both NPC and other cancers (multiple cancer trials). Moreover, 47 (10.2%) were Epstein-Barr virus (EBV)-related trials and 267 (57.8%) focused on metastatic/recurrent disease. Compared with NPC trials, the multiple cancer trials had a higher percentage of phase 1 (26.7% vs. 6.7%, P < 0.001) studies and more patients with metastatic/recurrent disease (72.5% vs. 41.9%, P < 0.001). Notably, non-EBV trials had more phase 2 or 3 (78.4% vs. 48.8%, P < 0.001) and interventional studies (89.5% vs. 70.7%, P = 0.002) than EBV trials. Obviously, more phase 2/3 or 3 trials were conducted in patients with non-metastatic/recurrent disease (29.4% vs. 4.9%, P < 0.001); however, metastatic/recurrent trials were more likely to be anticancer (94.6% vs. 63.6%, P < 0.001).The role of plasma EBV DNA in clinical trials is underestimated, and high-level randomized clinical trials should be performed for patients with metastatic/recurrent disease. |
| first_indexed | 2024-12-19T22:08:03Z |
| format | Article |
| id | doaj.art-3739f08d514c45ab9dcc571d00630b99 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-19T22:08:03Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3739f08d514c45ab9dcc571d00630b992022-12-21T20:03:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01135e019673010.1371/journal.pone.0196730The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database.Hao PengLei ChenYu-Pei ChenWen-Fei LiLing-Long TangAi-Hua LinYing SunJun MaClinical Trials have emerged as the main force in driving the development of medicine. However, little is known about the current status of clinical trials regarding nasopharyngeal carcinoma (NPC). This study aimed at providing a comprehensive landscape of NPC-related trials on the basis of ClinicalTrials.gov database.We used the keyword "nasopharyngeal carcinoma" to search the ClinicalTrials.gov database and assessed the characteristics of these trials.Up to December 30, 2016, 462 eligible trials in total were identified, of which 222 (48.0%) recruited only NPC (NPC trials) and the other 240 (52.0%) recruited both NPC and other cancers (multiple cancer trials). Moreover, 47 (10.2%) were Epstein-Barr virus (EBV)-related trials and 267 (57.8%) focused on metastatic/recurrent disease. Compared with NPC trials, the multiple cancer trials had a higher percentage of phase 1 (26.7% vs. 6.7%, P < 0.001) studies and more patients with metastatic/recurrent disease (72.5% vs. 41.9%, P < 0.001). Notably, non-EBV trials had more phase 2 or 3 (78.4% vs. 48.8%, P < 0.001) and interventional studies (89.5% vs. 70.7%, P = 0.002) than EBV trials. Obviously, more phase 2/3 or 3 trials were conducted in patients with non-metastatic/recurrent disease (29.4% vs. 4.9%, P < 0.001); however, metastatic/recurrent trials were more likely to be anticancer (94.6% vs. 63.6%, P < 0.001).The role of plasma EBV DNA in clinical trials is underestimated, and high-level randomized clinical trials should be performed for patients with metastatic/recurrent disease.http://europepmc.org/articles/PMC5931495?pdf=render |
| spellingShingle | Hao Peng Lei Chen Yu-Pei Chen Wen-Fei Li Ling-Long Tang Ai-Hua Lin Ying Sun Jun Ma The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database. PLoS ONE |
| title | The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database. |
| title_full | The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database. |
| title_fullStr | The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database. |
| title_full_unstemmed | The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database. |
| title_short | The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database. |
| title_sort | current status of clinical trials focusing on nasopharyngeal carcinoma a comprehensive analysis of clinicaltrials gov database |
| url | http://europepmc.org/articles/PMC5931495?pdf=render |
| work_keys_str_mv | AT haopeng thecurrentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT leichen thecurrentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT yupeichen thecurrentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT wenfeili thecurrentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT linglongtang thecurrentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT aihualin thecurrentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT yingsun thecurrentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT junma thecurrentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT haopeng currentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT leichen currentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT yupeichen currentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT wenfeili currentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT linglongtang currentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT aihualin currentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT yingsun currentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase AT junma currentstatusofclinicaltrialsfocusingonnasopharyngealcarcinomaacomprehensiveanalysisofclinicaltrialsgovdatabase |